정예희 (이화여자대학교 약학대학)

한빛사논문

조회619

이화여자대학교 약학대학

CV File 181 kb

Adv. Drug Deliv. Rev., 2023 Jul 7;200:114990 | https://doi.org/10.1016/j.addr.2023.114990 Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications

Michaela Jeong ¹, Yeji Lee ¹, Jeongeun Park ¹, Hyein Jung ¹, Hyukjin Lee ^{1 *}

¹College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, South Korea

^*Corresponding author: correspondence to Hyukjin Lee

Abstract

RNA therapeutics show a significant breakthrough for the treatment of otherwise incurable diseases and genetic disorders by regulating disease-related gene expression. The successful development of COVID-19 mRNA vaccines further emphasizes the potential of RNA therapeutics in the prevention of infectious diseases as well as in the treatment of chronic diseases. However, the efficient delivery of RNA into cells remains a challenge, and nanoparticle delivery systems such as lipid nanoparticles (LNPs) are necessary to fully realize the potential of RNA therapeutics. While LNPs provide a highly efficient platform for the in vivo delivery of RNA by overcoming various biological barriers, several challenges remain to be resolved for further development and regulatory approval. These include a lack of targeted delivery to extrahepatic organs and a gradual loss of therapeutic potency with repeated doses. In this review, we highlight the fundamental aspects of LNPs and their uses in the development of novel RNA therapeutics. Recent advances in LNP-based therapeutics and preclinical/clinical studies are overviewed. Lastly, we discuss the current limitations of LNPs and introduce breakthrough technologies that might overcome these challenges in future applications.

논문정보

형식Review Paper
게재일2023년 07월 (BRIC 등록일 2023-07-31)
연구진국내 연구진
분야 의약학 > 약학

댓글 작성 로그인

CV 열람하기

연락처 보기